Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.58 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 6/20 | 0.44 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | RHOC | P08134 | 2/20 | 0.43 |
| ▸ | RHOA | P61586 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.42 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15164922 | 0.91 | RAB9A (0.47) | ORAI1STIM1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL21786604 | 0.90 | ORAI1 (0.60) | ORAI1STIM1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2594838 | 0.86 | ORAI1 (0.56) | ORAI1STIM1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2592032 | 0.85 | ORAI1 (0.55) | ORAI1STIM1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL15164914 | 0.84 | KCNK3 (0.53) | RAB9ANPC1SMN1; SMN2TP53POLB | |
| SCHEMBL15171125 | 0.84 | SMN1; SMN2 (0.56) | RAB9ANPC1SMN1; SMN2TP53POLB | |
| SCHEMBL17805319 | 0.84 | ORAI1 (0.61) | ORAI1STIM1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL12155726 | 0.84 | ORAI1 (0.58) | ORAI1STIM1RAB9ALMNAKDM4E | |
| SCHEMBL12156171 | 0.82 | ORAI1 (0.64) | ORAI1STIM1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL15164936 | 0.82 | CRACR2A (0.50) | ORAI1STIM1RAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563759-B1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-2563759-B1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC (US) | 2022-04-06 | — | — | EP | disclosed |
| US-9353099-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353099-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353099-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150361075-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-12-17 | — | — | US | disclosed |
| US-20150361075-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-12-17 | — | — | US | disclosed |
| US-20150361075-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-12-17 | — | — | US | disclosed |
| US-9090612-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090612-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140243366-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8754219-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754219-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754219-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130203818-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203818-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203818-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2563759-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | Calcimedica, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011139765-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011139765-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243366-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ORAI1 1/4885STIM1 17/4885RAB9A 1174/4885 |
| US-20130203818-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ORAI1 1/4885STIM1 17/4885RAB9A 1174/4885 |
| US-20150361075-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ORAI1 1/4885STIM1 17/4885RAB9A 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.